Bronchoconstrictor effect of thrombin and thrombin receptor activating peptide in guinea‐pigs in vivo
- 29 January 1999
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 126 (2) , 478-484
- https://doi.org/10.1038/sj.bjp.0702303
Abstract
1. Several thrombin cellular effects are dependent upon stimulation of proteinase activated receptor-1 (PAR-1) localized over the cellular surface. Following activation by thrombin, a new N-terminus peptide is unmasked on PAR-1 receptor, which functions as a tethered ligand for the receptor itself. Synthetic peptides called thrombin receptor activating peptides (TRAPs), corresponding to the N-terminus residue unmasked, reproduce several thrombin cellular effects, but are devoid of catalytic activity. We have evaluated the bronchial response to intravenous administration of human alpha-thrombin or a thrombin receptor activating peptide (TRAP-9) in anaesthetized, artificially ventilated guinea-pigs. 2. Intravenous injection of thrombin (100 microkg(-1)) caused bronchoconstriction that was recapitulated by injection of TRAP-9 (1 mg kg(-1)). Animal pretreatment with the thrombin inhibitor Hirulog (10 mg kg(-1) i.v.) prevented thrombin-induced bronchoconstriction, but did not affect bronchoconstriction induced by TRAP-9. Both agents did not induce bronchoconstriction when injected intravenously to rats. 3. The bronchoconstrictor effect of thrombin and TRAP-9 was subjected to tolerance; however, in animals desensitized to thrombin effect, TRAP-9 was still capable of inducing bronchoconstriction, but not vice versa. 4. Depleting animals of circulating platelets prevented bronchoconstriction induced by both thrombin and TRAP-9. 5. Bronchoconstriction was paralleled by a biphasic change in arterial blood pressure, characterized by a hypotensive phase followed by a hypertensive phase. Thrombin-induced hypotension was not subject to tolerance and was inhibited by Hirulog; conversely, hypertension was subject to tolerance and was not inhibited by Hirulog. Hypotension and hypertension induced by TRAP-9 were neither subject to tolerance nor inhibited by Hirulog. 6. Our results indicate that thrombin causes bronchoconstriction in guinea-pigs through a mechanism that requires proteolytic activation of its receptor and the exposure of the tethered ligand peptide. Platelet activation might be triggered by the thrombin effect.Keywords
This publication has 38 references indexed in Scilit:
- Relaxant and Contractile Responses of Porcine Pulmonary Arteries to Thrombin and Thrombin Receptor Activating PeptidesSeminars in Thrombosis and Hemostasis, 1996
- Altered platelet function associated with the bronchial hyperresponsiveness accompanying nocturnal asthmaJournal of Allergy and Clinical Immunology, 1993
- Actions of thrombin and thrombin receptor peptide analogues in gastric and aortic smooth muscle: Development of bioassays for structure-activity studiesLife Sciences, 1992
- Essential groups in synthetic agonist peptides for activation of the platelet thrombin receptorBiochemistry, 1992
- A Role for α-Thrombin in Polymorphonuclear Leukocyte Recruitment During InflammationSeminars in Thrombosis and Hemostasis, 1992
- A thrombin receptor in resident rat peritoneal macrophagesExperimental Cell Research, 1991
- Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activationCell, 1991
- Late Phase Increase of Thrombin-Like Proteinase, Protein, Leukocytes in Bronchoalveolar Lavage (BAL) Fluid and Chemiluminescence of BAL after Ovalbumin Aerosol Inhalation by Actively Immunized RatsInternational Archives of Allergy and Immunology, 1991
- The specific binding of thrombin to human polymorphonuclear leucocytesScandinavian Journal of Clinical and Laboratory Investigation, 1987
- Monocyte Chemotaxis: Stimulation by Specific Exosite Region in ThrombinScience, 1983